In a report issued on December 17, Nick Corcoran from Acumen Capital maintained a Buy rating on CRH Medical (CRHM), with a price target of C$6.00. The company’s shares closed last Monday at $2.63.
According to TipRanks.com, Corcoran is ranked #1953 out of 7112 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CRH Medical with a $3.67 average price target, a 42.2% upside from current levels. In a report issued on December 17, Eight Capital also maintained a Buy rating on the stock with a C$4.50 price target.
See today’s analyst top recommended stocks >>
Based on CRH Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $30.35 million and GAAP net loss of $338K. In comparison, last year the company earned revenue of $30.41 million and had a net profit of $982.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRH Medical Corp. engages in the provision of gastroenterologists with services and products for the treatment of gastrointestinal diseases. It operates through the following business segments: Anesthesia Services, Product Sales, and Other. It also offers the CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The Other segment covers the corporate activities. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Read More on CRHM:
